Overview

A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

Status:
Not yet recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.
Phase:
Phase 2
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborator:
PharmaEssentia
Treatments:
Tenofovir
Ursodeoxycholic Acid